Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Clostridium difficile toxin A |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C6476H10000N1740O2010S45 |
Molar mass | 145836.11 g·mol−1 |
Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridium difficile infection.[1]
This drug, along with bezlotoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School.[2] The project was then licensed to Merck & Co., Inc. for further development and commercialization.[3]
A study compared it with bezlotoxumab (that targets CD toxin-B) and found Actoxumab less effective.[4]